Six Years, One Forged Prescription: Ruti Aga's Case Is About Medical Governance, Not the Drug

Ruti Aga won that half marathon in March. On a road in China, away from the crowd, not a single split time made it into the media report. There is no performance data in this report—no mark, no field strength, no stats. Just one fact: she won. Four months later, provisionally suspended from 10 September, she now faces a six-year ban after the Athletics Integrity Unit (AIU) ruling.

What this case will be remembered for is not a mare's age or a broken bone, but a forged prescription—written by a family member who was not a doctor, from a clinic that did not exist.

Context: The Arithmetic of Sanction

Let us start with the numbers, because this case is hidden in them. The AIU added two sanctions: two years for presence (methylprednisolone, WADA Prohibited List class S9—a glucocorticoid, not an anabolic steroid), and four years for tampering, because a fabricated document was produced. Six years total, effective from 10 September.

At 32, the entire 2028 Olympic cycle window has closed. If I look at the age curve—for Ethiopian women marathoners, 32 is the point where the peak begins and decline approaches—then a return at 38 means returning to a race where five or six runners in her own national team will be faster. This is not a sanction; it is career death.

Core Analysis: It Wasn't the Drug, It Was the Document

Here is what media reporting missed. Methylprednisolone was called a "prohibited steroid," which is technically wrong. It is a glucocorticoid, and under WADA's 2026 List, it is prohibited only in-competition—by injection, oral, or rectal routes. Meaning: a therapeutic injection in the knee, if given at the right time and by the right route, is entirely legal out-of-competition.

This is the most tragic part of the case. Aga had a legitimate defensive pathway: show medical records, prove timing, clarify route of administration. In S9 cases, "no fault" or "no significant fault" arguments often work. But she had a forged prescription made—and destroyed that defence herself.

According to the AIU statement, the "doctor" was a family member with no medical registration. He claimed to have used "an old prescription pad from a former workplace"—but that clinic did not exist. Three independent verification failures: clinic nonexistent, doctor unregistered, pad not genuine.

When I first read this statement, I remembered Kalinga Stadium in 2026—when I skipped the podium after Neeraj Chopra's gold and spoke to a Railways long jumper about sports-quota jobs. That is when I learned that the real story is not in the result but in the system that makes the result possible. The same applies here. Aga's case is not about the drug; it is about the medical system she did not have.

In my 28-year career, I have seen dozens of East African road-running cases. One pattern is clear: when a runner gets injured and has no credentialed team physician, treatment becomes informal. A glucocorticoid injection is the cheapest and easiest fix—mask the pain, run the race, protect the appearance fee. The problem is that same informality becomes fatal at the time of investigation.

Contrarian Angle: Is Six Years Disproportionate?

Here is an uncomfortable question that should arise after the AIU decision. Six years for a substance with no proven performance-enhancing benefit for endurance? Glucocorticoids reduce pain and inflammation—they do not build muscle like steroids, do not increase oxygen like EPO. Yes, they can indirectly help by making an injured runner able to race, but why has WADA kept them prohibited only in-competition? Because out-of-competition treatment is legitimate.

So the question is not whether Aga should have been sanctioned—forgery is a serious offence, and four years is appropriate. The question is: is the combination of four years for tampering and two years for presence proportionate in a case where the original substance has no proven benefit? This AIU ruling will become a weapon for those who argue that enforcement against African road runners is inconsistent.

Something else bothers me. When I stood in the mixed zone at Kalinga in 2026, I saw how athletes with sports-quota jobs—no medical support, no agent, no TUE infrastructure—are the weakest link in the system. Aga had an agent and management, yet her medical support was so hollow that a family member became "doctor." That question is outside the AIU's jurisdiction, but it is the biggest lesson of this case.

Takeaway: The Document Is the New Battlefield

Aga's 2026 Tokyo Marathon title and three World Marathon Majors second places—these facts will remain in her record, because the ban is tied to that March race, and earlier results were not annulled. But her career is effectively over.

Those who think this is an isolated case are wrong. There is a clear clustering in AIU East African road-running cases: first a substance violation, then tampering. This means the enforcement frontier has shifted from "detection" to "document verification." China's label race circuit—where large appearance fees, deep East African fields, and AIU testing coexist—is now a high-scrutiny zone.

If I were to leave one question, it would be: was there any statement from the Ethiopian athletics federation? The AIU spoke, but what accountability was established at the national level? Until that question is asked, the next Ruti Aga case will already be in preparation. The split time is a story, not a verdict—but a forged prescription is a verdict, and its document is now public.